Patents by Inventor Martin Scobie

Martin Scobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy
    Patent number: 11504368
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: November 22, 2022
    Assignee: THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING
    Inventors: Christoffer Bengtsson, Sanjay Borhade, Martin Haraldsson, Thomas Helleday, Martin Henriksson, Evert Homan, Cynthia Paulin, Lars Sandberg, Martin Scobie, Pål Stenmark, Karl Vallin
  • MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
    Patent number: 10632125
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: April 28, 2020
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Roland Julius Yu Fiskesund
  • MTH1 inhibitors for treatment of cancer
    Patent number: 10179790
    Abstract: A compound of formula I, (I) or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: January 15, 2019
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Sylvain Jacques, Evert Homan, Thomas Helleday
  • Pyrimidine-2,4-diamine derivatives for treatment of cancer
    Patent number: 10174029
    Abstract: A compound of formula I, or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: January 8, 2019
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Thomas Helleday, Tobias Koolmeister, Sylvain Jacques
  • MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS
    Publication number: 20190000856
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Application
    Filed: August 31, 2018
    Publication date: January 3, 2019
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Roland Julius Yu Fiskesund
  • MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
    Patent number: 10064869
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: September 4, 2018
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Matthieu Desroses, Marie-Caroline Jacques-Cordonnier, Roland Julius Yu Fiskesund
  • Pyrimidine-2,4-diamine derivatives for treatment of cancer
    Patent number: 9944640
    Abstract: A compound of formula I, or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 17, 2018
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Thomas Helleday, Tobias Koolmeister, Sylvain Jacques, Matthieu Desroses, Marie-Caroline Jacques-Cordonnier
  • MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS
    Publication number: 20170196873
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 13, 2017
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Matthieu Desroses, Marie-Caroline Jacques-Cordonnier, Roland Julius Yu Fiskesund
  • MTH1 INHIBITORS FOR TREATMENT OF CANCER
    Publication number: 20170197976
    Abstract: A compound of formula I, (I) or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 13, 2017
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Sylvain Jacques, Evert Homan, Thomas Helleday
  • Pyrimidine-2,4-diamine derivatives for treatment of cancer
    Patent number: 9604937
    Abstract: A compound of formula (I), or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: March 28, 2017
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Thomas Helleday, Tobias Koolmeister, Sylvain Jacques
  • Pyrimidine-2,4-Diamine Derivatives for Treatment of Cancer
    Publication number: 20160002175
    Abstract: A compound of formula (I), or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Application
    Filed: November 26, 2013
    Publication date: January 7, 2016
    Inventors: Martin Scobie, Thomas Helleday, Tobias Koolmeister, Sylvain Jacques, Matthieu Desroses, Marie-Caroline Jacques-Cordonnier
  • Substituted octahydroisoindoles
    Publication number: 20070149600
    Abstract: The invention relates to compounds of the general formula (I) wherein R1, R2, R3, Ar, and X are as defined herein, or a pharmaceutically acceptable salt, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).
    Type: Application
    Filed: April 24, 2006
    Publication date: June 28, 2007
    Inventors: Andrew Browning, Martin Scobie
  • New compounds
    Publication number: 20050239841
    Abstract: The invention relates to compounds of the general formula (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, R9, Ar, and X are as defined in the description, or a pharmaceutically acceptable salt, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).
    Type: Application
    Filed: November 24, 2004
    Publication date: October 27, 2005
    Inventors: Andrew Browning, Jonas Nilsson, Martin Scobie, Johan Angbrant, Rune Ringom
  • Compounds
    Publication number: 20050192339
    Abstract: The invention relates to compounds of the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, and X are as defined in the description, or pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).
    Type: Application
    Filed: November 23, 2004
    Publication date: September 1, 2005
    Inventors: Andrew Browning, Martin Scobie
  • Compounds and their use
    Patent number: 6756377
    Abstract: The invention relates to compounds of the general formula (I) wherein R1, R2 and R3 are as described in the specification, which compounds are ligands to the serotonin 5-HT2c receptor.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: June 29, 2004
    Assignee: Biovitrum AB
    Inventors: Björn M. Nilsson, Martin Scobie
  • Novel compounds and their use
    Publication number: 20020103204
    Abstract: The invention relates to compounds of the general formula (I) 1
    Type: Application
    Filed: November 19, 2001
    Publication date: August 1, 2002
    Inventors: Bjorn M. Nilsson, Martin Scobie